A cause de la limite du nombre de caractères dans les titres des brèves, nous avons du raccourcir la traduction. Le voici en entier
"Titres d'anticorps anti-récepteurs de l'acétylcholine et évolution clinique après la vaccination antigrippale chez des patients atteints de myasthénie grave: un essai contrôlé randomisé à double insu (essai clinique). "
Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29337134[ligne][/ligne]
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
[ligne][/ligne]
Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).
Tackenberg B1, Schneider M2, Blaes F3, Eienbröker C2, Schade-Brittinger C4, Wellek A2, Deschauer M5, Eickmann M6, Klenk HD6, Müller HH7, Sommer N8.
EBioMedicine. 2018 Jan 10. pii: S2352-3964(18)30007-0. doi: 10.1016/j.ebiom.2018.01.007.
Abstract
- BACKGROUND:
It is a continuous matter of discussion whether immune activation by vaccination in general and Influenza vaccination in particular increases the risk for clinical deterioration of autoimmune diseases. This prospective study investigated the serological and clinical course of autoimmune Myasthenia gravis (MG) after a seasonal influenza vaccination.
- METHODS:
This randomized, placebo-controlled, double-blind study enrolled MG patients with antibodies against acetylcholine-receptors (AChR-ab). They were allocated to receive seasonal influenza vaccine or placebo. The primary endpoint was the relative change of AChR-ab-titer over 12weeks. A relative increase of 20% was set as non-inferiority margin. Secondary endpoints were clinical changes in the modified Quantitative Myasthenia Gravis Score (QMG), increase of anti-influenza-ELISA-antibodies, and changes of treatment. The study is registered with Clinicaltrialsregister.eu, EudraCT number 2006-004374-27.
- FINDINGS:
62 patients were included. Mean±standard deviation (median) in the vaccine and placebo group were AChR-ab-titer changes of -6.0%±23.3% (-4.0%) and -2.8%±22.0% (-0.5%) and QMG score changes of -0.08±0.27 (0.17) and 0.11±0.31 (0.00), respectively. The difference between groups (Hodges-Lehmann estimate with 95% CI) was - for the AChR-ab-titer change 4·0% [-13.3%, 4.5%] (p=0.28 for testing a difference, p<0.0001 for testing non-inferiority) and for the QMG change 0·00 [-0.17, 0.00] (p=0.79 for testing a difference). The occurrence of 74 adverse events (AE) was comparable between groups. The most common AE was flu-like symptoms. One serious AE (hospitalisation following gastrointestinal haemorrhage) in the verum group was not related to the vaccine.
- INTERPRETATION:
Influenza vaccination in MG is safe. Uprating the potential risk of a severe course of MG exacerbation during influenza infection compared to the 95% CI differences for the endpoints, vaccination is principally indicated in this patient population.
| Message d' un membre de l'équipe technique |
| Pour les utilisateurs d'I-phone ci-dessous le lien vers Google Trad https://translate.google.fr/translate?h ... 2F29337134 |
| Message d' un membre de l'équipe technique |
| Nous utilisons des services automatiques de traduction fournis par Yandex ou Google. Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils. |
